Suppr超能文献

Ivor-Lewis 与 Sweet 食管癌切除术治疗食管鳞癌的比较:一项随机临床试验。

Comparison of Ivor-Lewis vs Sweet esophagectomy for esophageal squamous cell carcinoma: a randomized clinical trial.

机构信息

Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

JAMA Surg. 2015 Apr;150(4):292-8. doi: 10.1001/jamasurg.2014.2877.

Abstract

IMPORTANCE

Sweet esophagectomy is performed widely in China, while the Ivor-Lewis procedure, with potential benefit of an extended lymphadenectomy, is limitedly conducted owing to concern for a higher risk for morbidity. Thus, the role of the Ivor-Lewis procedure for thoracic esophageal cancer needs further investigation.

OBJECTIVE

To determine whether Ivor-Lewis esophagectomy is associated with increased postoperative complications compared with the Sweet procedure.

DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was conducted from May 2010 to July 2012 at Fudan University Shanghai Cancer Center, Shanghai, China, of 300 patients with resectable squamous cell carcinoma in the middle and lower third of the thoracic esophagus. Intent-to-treat analysis was performed.

INTERVENTIONS

Patients were randomly assigned to receive either the Ivor-Lewis (n = 150) or Sweet (n = 150) esophagectomy.

MAIN OUTCOMES AND MEASURES

The primary outcome of this clinical trial was operative morbidity (any surgical or nonsurgical complications). Secondary outcomes included oncologic efficacy (number of lymph nodes resected and positive lymph nodes), postoperative mortality (30-day and in-hospital mortality), and patient discharge.

RESULTS

Resection without macroscopical residual (R0/R1) was achieved in 149 of 150 patients in each group. Although there was no significant difference between the 2 groups regarding the incidence of each single complication, a significantly higher morbidity rate was found in the Sweet group (62 of 150 [41.3%]) than in the Ivor-Lewis group (45 of 150 [30%]) (P = .04). More patients in the Sweet group (8 of 150 [5.3%]) received reoperations than in the Ivor-Lewis group (1 of 150 [0.7%]) (P = .04). The median hospital stay was 18 days in the Sweet group vs 16 days in the Ivor-Lewis group (P = .002). Postoperative mortality rates in the Ivor-Lewis (1 of 150) and Sweet (3 of 150) groups were 0.7% and 2.0%, respectively (P = .25). More lymph nodes were removed during Ivor-Lewis esophagectomy than during the Sweet procedure (22 vs 18, P < .001).

CONCLUSIONS AND RELEVANCE

Early results of this study demonstrate that the Ivor-Lewis procedure can be performed with lower rates of postoperative complications and more lymph node retrieval. Ivor-Lewis and Sweet esophagectomies are both safe procedures with low operative mortalities.

TRIAL REGISTRATION

clinicaltrials.gov Identifier:NCT01047111.

摘要

重要性

在中国,广泛施行经胸食管切除术(Sweet 手术),而 Ivor-Lewis 手术虽然潜在地具有扩大淋巴结清扫术的优势,但由于对更高发病率的担忧,目前施行范围有限。因此,Ivor-Lewis 手术治疗胸段食管癌的作用仍需要进一步研究。

目的

确定 Ivor-Lewis 食管切除术与 Sweet 手术相比,是否会增加术后并发症。

设计、设置和参与者:这是一项 2010 年 5 月至 2012 年 7 月在复旦大学附属肿瘤医院进行的、针对 300 例可切除的中段和下段胸段食管鳞状细胞癌患者的随机临床试验。采用意向治疗分析。

干预措施

患者被随机分配接受 Ivor-Lewis(n = 150)或 Sweet(n = 150)食管切除术。

主要结局和测量指标

本临床试验的主要结局是手术发病率(任何手术或非手术并发症)。次要结局包括肿瘤学疗效(切除的淋巴结数量和阳性淋巴结数量)、术后死亡率(30 天和院内死亡率)和患者出院情况。

结果

每组各有 150 例患者达到无肉眼残留的切除(R0/R1)。虽然 2 组之间每种单一并发症的发生率没有显著差异,但 Sweet 组(62/150 [41.3%])的发病率显著高于 Ivor-Lewis 组(45/150 [30%])(P = .04)。Sweet 组(8/150 [5.3%])需要再次手术的患者多于 Ivor-Lewis 组(1/150 [0.7%])(P = .04)。Sweet 组的中位住院时间为 18 天,而 Ivor-Lewis 组为 16 天(P = .002)。Ivor-Lewis 组(1/150)和 Sweet 组(3/150)的术后死亡率分别为 0.7%和 2.0%(P = .25)。Ivor-Lewis 食管切除术比 Sweet 手术切除的淋巴结更多(22 个 vs 18 个,P < .001)。

结论和相关性

本研究的早期结果表明,Ivor-Lewis 手术可降低术后并发症发生率,并获得更多的淋巴结。Ivor-Lewis 和 Sweet 食管切除术均是安全的手术,手术死亡率低。

试验注册

clinicaltrials.gov 标识符:NCT01047111。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验